Therapeutic Drug Monitoring for Tomorrow

Overview

Journal Eur J Clin Pharmacol

Specialty Pharmacology

Date 2013 May 4

PMID 23640185

Citations 19

Authors

Erik Eliasson

Jonatan D Lindh

Rickard E Malmstrom

Olof Beck

Marja-Liisa Dahl

Affiliations

Soon will be listed here.

Abstract

Therapeutic drug monitoring (TDM) represents an early approach to personalised medicine. It helps the clinician to individualise drug treatment and guide dosage to reach systemic drug concentrations associated with therapeutic efficacy and/or to reduce the risk of concentration-dependent adverse effects. Well into the fifth decade of TDM as a service to healthcare, this concept is still expanding, and new areas for clinical implementation continue to emerge. The aim of this overview is to discuss promising new therapeutic areas in future TDM services, how to improve the clinical interpretation of single drug measurements and how recent technology development opens the doors to research and new applications.

Citing Articles

Influence of genetic polymorphisms on pharmacokinetics and treatment response of mycophenolic acid: a scoping review.

Yow H, Ikawati M, Siswanto S, Hermawan A, Rahmat A, Tan J Pharmacogenomics. 2024; 25(5-6):259-288.

PMID: 38884938 PMC: 11388138. DOI: 10.1080/14622416.2024.2344430.

Innovative Solid-Phase Extraction Strategies for Improving the Advanced Chromatographic Determination of Drugs in Challenging Biological Samples.

Mahdavijalal M, Petio C, Staffilano G, Mandrioli R, Protti M Molecules. 2024; 29(10).

PMID: 38792139 PMC: 11124106. DOI: 10.3390/molecules29102278.

Revolutionizing Precision Medicine: Exploring Wearable Sensors for Therapeutic Drug Monitoring and Personalized Therapy.

Liu Y, Li J, Xiao S, Liu Y, Bai M, Gong L Biosensors (Basel). 2023; 13(7).

PMID: 37504123 PMC: 10377150. DOI: 10.3390/bios13070726.

Solid Phase-Based Microextraction Techniques in Therapeutic Drug Monitoring.

Soares S, Rosado T, Barroso M, Gallardo E Pharmaceutics. 2023; 15(4).

PMID: 37111541 PMC: 10142207. DOI: 10.3390/pharmaceutics15041055.

Therapeutic drug monitoring practices of anti-infectives: An Asia-wide cross-sectional survey.

Hou J, Marriott D, Cattaneo D, Stocker S, Stojanova J, Alffenaar J Front Pharmacol. 2022; 13:992354.

PMID: 36299881 PMC: 9589087. DOI: 10.3389/fphar.2022.992354.

References

Birkett D, Brosen K, Cascorbi I, Gustafsson L, Maxwell S, Rago L . Clinical pharmacology in research, teaching and health care: Considerations by IUPHAR, the International Union of Basic and Clinical Pharmacology. Basic Clin Pharmacol Toxicol. 2010; 107(1):531-59. DOI: 10.1111/j.1742-7843.2010.00602.x. View

Hazlewood K, Brouse S, Pitcher W, Hall R . Vancomycin-associated nephrotoxicity: grave concern or death by character assassination?. Am J Med. 2010; 123(2):182.e1-7. PMC: 2813201. DOI: 10.1016/j.amjmed.2009.05.031. View

Pasqualotto A, Howard S, Moore C, Denning D . Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother. 2007; 59(4):791-3. DOI: 10.1093/jac/dkl550. View

Carlquist J, Anderson J . Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation. 2011; 124(23):2554-9. DOI: 10.1161/CIRCULATIONAHA.111.019737. View

Wadelius M, Chen L, Lindh J, Eriksson N, Ghori M, Bumpstead S . The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2008; 113(4):784-92. PMC: 2630264. DOI: 10.1182/blood-2008-04-149070. View

Asberg M, CRONHOLM B, Sjoqvist F, Tuck D . Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J. 1971; 3(5770):331-4. PMC: 1798656. DOI: 10.1136/bmj.3.5770.331. View

Dahl M, Bertilsson L . Genetically variable metabolism of antidepressants and neuroleptic drugs in man. Pharmacogenetics. 1993; 3(2):61-70. DOI: 10.1097/00008571-199304000-00001. View

Lazo-Langner A, Kovacs M . Predicting warfarin dose. Curr Opin Pulm Med. 2010; 16(5):426-31. DOI: 10.1097/MCP.0b013e32833b1c6c. View

Roberts J, Ulldemolins M, Roberts M, McWhinney B, Ungerer J, Paterson D . Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010; 36(4):332-9. DOI: 10.1016/j.ijantimicag.2010.06.008. View

10.

Meyer M, Maurer H . Current applications of high-resolution mass spectrometry in drug metabolism studies. Anal Bioanal Chem. 2012; 403(5):1221-31. DOI: 10.1007/s00216-012-5807-z. View

11.

Duhme D, Greenblatt D, Koch-Weser J . Reduction of digoxin toxicity associated with measurement of serum levels. A report from the Boston Collaborative Drug Surveillance Program. Ann Intern Med. 1974; 80(4):516-9. DOI: 10.7326/0003-4819-80-4-516. View

12.

Gallardo E, Barroso M, Queiroz J . Current technologies and considerations for drug bioanalysis in oral fluid. Bioanalysis. 2010; 1(3):637-67. DOI: 10.4155/bio.09.23. View

13.

Patel M, Mahaffey K, Garg J, Pan G, Singer D, Hacke W . Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365(10):883-91. DOI: 10.1056/NEJMoa1009638. View

14.

Sime F, Roberts M, Peake S, Lipman J, Roberts J . Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care. 2012; 2(1):35. PMC: 3460787. DOI: 10.1186/2110-5820-2-35. View

15.

De Molina F, Ferrer R . Appropriate antibiotic dosing in severe sepsis and acute renal failure: factors to consider. Crit Care. 2011; 15(4):175. PMC: 3387596. DOI: 10.1186/cc10298. View

16.

Roberts D, Roberts J, Roberts M, Liu X, Nair P, Cole L . Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med. 2012; 40(5):1523-8. DOI: 10.1097/CCM.0b013e318241e553. View

17.

Sjoqvist F, Eliasson E . The convergence of conventional therapeutic drug monitoring and pharmacogenetic testing in personalized medicine: focus on antidepressants. Clin Pharmacol Ther. 2007; 81(6):899-902. DOI: 10.1038/sj.clpt.6100188. View

18.

Bertilsson L, Carrillo J, Dahl M, Llerena A, Alm C, Bondesson U . Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol. 1994; 38(5):471-3. PMC: 1364883. DOI: 10.1111/j.1365-2125.1994.tb04385.x. View

19.

Van Herendael B, Jeurissen A, Tulkens P, Vlieghe E, Verbrugghe W, Jorens P . Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin?. Ann Intensive Care. 2012; 2(1):22. PMC: 3532155. DOI: 10.1186/2110-5820-2-22. View

20.

Brunen S, Vincent P, Baumann P, Hiemke C, Havemann-Reinecke U . Therapeutic drug monitoring for drugs used in the treatment of substance-related disorders: literature review using a therapeutic drug monitoring appropriateness rating scale. Ther Drug Monit. 2011; 33(5):561-72. DOI: 10.1097/FTD.0b013e31822fbf7c. View